Patents by Inventor Paul Brazeau

Paul Brazeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9961141
    Abstract: Techniques and systems for storing and retrieving data storage devices of a data storage system are disclosed. In some embodiments, inventory holders are used to store data storage devices used by a data storage system. When data is to be transacted with the data storage devices, mobile drive units locate appropriate inventory holders and transport them to a device reading station, where an appropriate device retrieval unit transacts the data. In some embodiments, each inventory holder includes a plurality of trays that are independently accessible to the device retrieval unit. After the data has been transacted, the data storage devices are returned to the appropriate inventory holders, and the inventory holders are placed by the mobile drive units in locations where they may be accessed in response to further data transactions.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: May 1, 2018
    Assignee: AMAZON TECHNOLOGIES, INC.
    Inventors: James Raymond Allard, Paul David Franklin, Samuel Rubin Barrett, Jeremiah Brazeau, Jeffrey Allen Dzado, James Caleb Kirschner, David Levy, Brent James Lutz, Andrew Brenden Tinka, Colin Laird Lazier
  • Patent number: 8252341
    Abstract: The present invention concerns a novel process for isolating growth and differentiating factors present in colostrum, all in a natural way. This process is characterized by maturation steps (controlled mild acid hydrolysis) and physical steps (molecular filtration) which optimize recovery of measured growth factors and their ability to entice a response on human cells. Advantageously, this process allows the derivation and isolation of growth and differentiating factors with highly disparate sizes (or molecule weights) in pools. These pools can be used in select and varied ways, including cosmetic, cosmeceutical, nutraceutical, dermatological, pharmaceutical, medical and veterinary applications. It can also be used as a replacement to fetal calf serum to promote cell proliferation, and above all, cell differentiation.
    Type: Grant
    Filed: September 14, 2005
    Date of Patent: August 28, 2012
    Inventor: Paul Brazeau
  • Publication number: 20090081181
    Abstract: The present invention concerns a novel process for isolating growth and differentiating factors present in colostrum, all in a natural way. This process is characterized by maturation steps (controlled mild acid hydrolysis) and physical steps (molecular filtration) which optimize recovery of measured growth factors and their ability to entice a response on human cells. Advantageously, this process allows the derivation and isolation of growth and differentiating factors with highly disparate sizes (or molecule weights) in pools. These pools can be used in select and varied ways, including cosmetic, cosmeceutical, nutraceutical, dermatological, pharmaceutical, medical and veterinary applications. It can also be used as a replacement to fetal calf serum to promote cell proliferation, and above all, cell differentiation.
    Type: Application
    Filed: September 14, 2005
    Publication date: March 26, 2009
    Applicant: NEXCELL BIOSCIENCES, INC
    Inventor: Paul Brazeau
  • Publication number: 20040171534
    Abstract: The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.
    Type: Application
    Filed: August 7, 2002
    Publication date: September 2, 2004
    Applicant: Theratechnologies, Inc.
    Inventors: Denis Gravel, Abdelkrim Habi, Paul Brazeau
  • Publication number: 20040081703
    Abstract: The present invention relates to cartilage extracts and to a method of producing the same. Shark cartilage extracts having anti-angiogenic, anti-tumor, anti-inflammatory and anti-collagenolytic activities have been obtained by an improved process. The process comprises the steps of obtaining a crude cartilage extract in an aqueous solution, this crude extract being fractionated to recover molecules of a molecular weight less than about 500 kDa. Some of the biologically active components of the extract are prepared by further fractionation. The cartilage extract can be used for treating diseases or conditions having etiological components selected from the group consisting of tumor proliferation, angiogenesis, inflammation, metalloprotease activity and collagenolysis. Several cosmetic applications based on the capacity of the liquid extract to improve skin conditions are also disclosed. A simple and efficient process for the preparation of cartilage extracts is also disclosed.
    Type: Application
    Filed: October 17, 2003
    Publication date: April 29, 2004
    Applicant: Les Laboratoires Aeterna, Inc.
    Inventors: Eric Dupont, Paul Brazeau, Christina Juneau, Daniel H. Maes, Kenneth Marenus, Richard Beliveau
  • Patent number: 6635285
    Abstract: The present invention relates to cartilage extracts and to a method of producing the same. Shark cartilage extracts having anti-angiogenic, anti-tumor, anti-inflammatory and anti-collagenolytic activities have been obtained by an improved process. The process comprises the steps of obtaining a crude cartilage extract in an aqueous solution, this crude extract being fractionated to recover molecules of a molecular weight less than about 500 kDa. Some of the biologically active components of the extract are prepared by further fractionation. The cartilage extract can be used for treating diseases or conditions having etiological components selected from the group consisting of tumor proliferation, angiogenesis, inflammation, metalloprotease activity and collagenolysis. Several cosmetic applications based on the capacity of the liquid extract to improve skin conditions are also disclosed. A simple and efficient process for the preparation of cartilage extracts is also disclosed.
    Type: Grant
    Filed: February 7, 2002
    Date of Patent: October 21, 2003
    Assignee: Les Laboratoires Aeterna, Inc.
    Inventors: Éric Dupont, Paul Brazeau, Christina Juneau, Daniel H. Maes, Kenneth Marenus, Richard Béliveau
  • Publication number: 20030013858
    Abstract: The present invention relates to cartilage extracts and to a method of producing the same. Shark cartilage extracts having anti-angiogenic, anti-tumor, anti-inflammatory and anti-collagenolytic activities have been obtained by an improved process. The process comprises the steps of obtaining a crude cartilage extract in an aqueous solution, this crude extract being fractionated to recover molecules of a molecular weight less than about 500 kDa. Some of the biologically active components of the extract are prepared by further fractionation. The cartilage extract can be used for treating diseases or conditions having etiological components selected from the group consisting of tumor proliferation, angiogenesis, inflammation, metalloprotease activity and collagenolysis. Several cosmetic applications based on the capacity of the liquid extract to improve skin conditions are also disclosed. A simple and efficient process for the preparation of cartilage extracts is also disclosed.
    Type: Application
    Filed: February 7, 2002
    Publication date: January 16, 2003
    Applicant: AEeterna Laboratories, Inc.
    Inventors: Eric Dupont, Paul Brazeau, Christina Juneau, Daniel H. Maes, Kenneth Marenus, Richard Beliveau
  • Patent number: 6458764
    Abstract: The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: October 1, 2002
    Assignee: Theratechnologies Inc.
    Inventors: Denis Gravel, Abdelkrim Habi, Paul Brazeau
  • Patent number: 6380366
    Abstract: The present invention relates to cartilage extracts and to a method of producing the same. Shark cartilage extracts having anti-angiogenic, anti-tumor, anti-inflammatory and anti-collagenolytic activities have been obtained by an improved process. The process comprises the steps of obtaining a crude cartilage extract in an aqueous solution, this crude extract being fractionated to recover molecules of a molecular weight less than about 500 kDa. Some of the biologically active components of the extract are prepared by further fractionation. The cartilage extract can be used for treating diseases or conditions having etiological components selected from the group consisting of tumor proliferation, angiogenesis, inflammation, metalloprotease activity and collagenolysis. Several cosmetic applications based on the capacity of the liquid extract to improve skin conditions are also disclosed. A simple and efficient process for the preparation of cartilage extracts is also disclosed.
    Type: Grant
    Filed: February 15, 2000
    Date of Patent: April 30, 2002
    Assignee: Les Laboratoires Aeterna Inc.
    Inventors: Éric Dupont, Paul Brazeau, Christina Juneau, Richard Béliveau
  • Patent number: 6194384
    Abstract: The present invention relates to a long-acting galenical formulation of GRF peptides, GRF and/or analogs thereof which comprises about 1 to about 100 mg of a GRF peptide, fragment or analog thereof pressed from about 1 to about 100 kg/mm2 in a tablet for parenteral administration, whereby these GRF peptides are released as the tablet is eroded.
    Type: Grant
    Filed: August 18, 1998
    Date of Patent: February 27, 2001
    Assignee: Theratechnologies, Inc.
    Inventors: Paul Brazeau, Denis Gravel
  • Patent number: 6106544
    Abstract: The present invention relates to a device for closing cutaneous wounds without sutures, which comprises a pair of three-dimensionally flexible strips adopted to be positioned on each side of a wound and formed of a plurality of laterally spaced apart elongated anchoring members extending side-by-side in succession and transversely of the wound and being interconnected in a three-dimensionally flexible manner to follow the lips of an open wound.
    Type: Grant
    Filed: November 30, 1998
    Date of Patent: August 22, 2000
    Assignee: Theratechnologies, Inc.
    Inventor: Paul Brazeau
  • Patent number: 6028118
    Abstract: The present invention relates to cartilage extracts and to a method of producing the same. Shark cartilage extracts having anti-angiogenic, anti-tumoral, anti-inflammatory and anti-collagenolytic activities have been obtained by an improved process. The process comprises the steps of obtaining a homogenate of cartilage in an aqueous solution, this homogenate being separated in a solid fraction (SOLID EXTRACT) and a liquid fraction which was further fractionated to obtain a LIQUID EXTRACT having molecules of a molecular weight comprised between 0 to 500 kDa. The composition of the liquid extract has then been investigated by different ways. Further fractionation of this extract led to the preliminary characterization of some of its active components.
    Type: Grant
    Filed: August 8, 1996
    Date of Patent: February 22, 2000
    Assignee: Les Laboratoires Aeterna Inc.
    Inventors: Eric Dupont, Paul Brazeau, Christina Juneau, Daniel H. Maes, Kenneth Marenus
  • Patent number: 6025334
    Abstract: The present invention relates to cartilage extracts and to a method of producing the same. Shark cartilage extracts having anti-angiogenic, direct anti-tumor proliferating, anti-inflammatory and anti-collagenolytic activities have been obtained by an improved process. The process comprises the steps of obtaining a homogenate of cartilage in an aqueous solution, this homogenate being centrifuged and further fractionated to obtain a total extract having molecules of a molecular weight comprised between 0 to 500 KDa. The composition of the liquid extract has then been investigated by different ways. Further fractionation of this extract led to the preliminary characterization of some of its active components. Due to the multiplicity of biological activities of the total liquid extract, it can be used for treating numerous diseases or conditions such as those having components selected from the group consisting of tumor proliferation, angiogenesis, inflammation and collagenolysis.
    Type: Grant
    Filed: October 30, 1995
    Date of Patent: February 15, 2000
    Assignee: Les Laboratoires Aeterna Inc.
    Inventors: Eric Dupont, Paul Brazeau, Christina Juneau, Daniel H. Maes, Kenneth Marenus
  • Patent number: 6020311
    Abstract: The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.
    Type: Grant
    Filed: September 8, 1998
    Date of Patent: February 1, 2000
    Assignee: Theratechnologies, Inc.
    Inventors: Paul Brazeau, Denis Gravel
  • Patent number: 5985839
    Abstract: The present invention relates to shark cartilage extracts and to a method of producing the same, these extracts having anti-angiogenic properties (reduction of the area of blood vessels observed in vivo on experimentally induced tumors), tumor regressive activity in vivo as well as demonstrating a direct inhibitory effect on tumor cell lines. This process does not involve any denaturing solvent or product and does not involve the use of any enzymes. It consists of obtaining a blend of whole cartilage in an aqueous solution of neutral pH, preferably pure water, this blend being centrifuged and the pellet and supernatant kept for further processing. The pellet is lyophilized and tested for anti-tumor and anti-angiogenic activities in vivo and in vitro, with or without supernatant. The supernatant has been shown to have anti-angiogenic and tumor regressive activities in vivo. The composition of the supernatant has then been investigated by different ways.
    Type: Grant
    Filed: October 8, 1996
    Date of Patent: November 16, 1999
    Assignee: Les Laboratories Aeterna Inc.
    Inventors: Eric Dupont, Paul Brazeau, Christian Juneau
  • Patent number: 5939386
    Abstract: The present invention relates to chimeric fatty body-pro-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-pro-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring one or several hydrophobic tails to the GRF, or by substituting one or several amino-acids by a pseudomicellar residue in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.
    Type: Grant
    Filed: August 23, 1996
    Date of Patent: August 17, 1999
    Assignee: Theratechnologies Inc.
    Inventors: Michel Ibea, Thierry Abribat, Paul Brazeau
  • Patent number: 5861379
    Abstract: The present invention relates to chimeric fatty body-pro-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-pro-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring one or several hydrophobic tails to the GRF, or by substituting one or several amino-acids by a pseudomicellar residue in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.
    Type: Grant
    Filed: August 23, 1996
    Date of Patent: January 19, 1999
    Assignee: Theratechnologies Inc.
    Inventors: Michel Ibea, Thierry Abribat, Paul Brazeau
  • Patent number: 5843123
    Abstract: The present invention relates to a device for closing cutaneous wounds without sutures, which comprises a pair of three-dimensionally flexible strips adopted to be positioned on each side of a wound and formed of a plurality of laterally spaced apart elongated anchoring members extending side-by-side in succession and transversely of the wound and being interconnected in a three-dimensionally flexible manner to follow the lips of an open wound.
    Type: Grant
    Filed: September 6, 1996
    Date of Patent: December 1, 1998
    Assignee: Theratechnologies Inc.
    Inventor: Paul Brazeau
  • Patent number: 5834418
    Abstract: The present invention relates to a process for the preparation of porcine platelet-extract containing matured growth factors, which comprises the steps of: a) centrifuging whole porcine blood at about 1000 g to about 5000 g to isolate the platelets from the platelet-rich-plasma; b) resuspending the isolated platelets of step a) in Plasma-Lyte A and centrifuging to concentrate the platelets; c) washing the concentrated platelets of step b); d) lyophilizing the washed platelets of step c); whereby causing lysis of the platelets and producing the platelet extract in optimal amount.
    Type: Grant
    Filed: March 20, 1996
    Date of Patent: November 10, 1998
    Assignee: Theratechnologies, Inc.
    Inventors: Paul Brazeau, Thierry Abribat, Michel Ibea, Michele Boushira
  • Patent number: 5817627
    Abstract: The present invention relates to a long-acting galenical formulation of GRF peptides, pro-GRF and/or analogs thereof which comprises about 1 to about 100 mg of a GRF peptide, fragment or analog thereof pressed from about 1 to about 100 kg/mm.sup.2 in a tablet for parenteral administration, whereby these GRF peptides are released as the tablet is eroded.
    Type: Grant
    Filed: June 14, 1996
    Date of Patent: October 6, 1998
    Assignee: Theratechnologies Inc.
    Inventors: Paul Brazeau, Thierry Abribat, Michel Ibea